恩华药业
(002262)
| 流通市值：198.18亿 | | | 总市值：227.74亿 |
| 流通股本：8.84亿 | | | 总股本：10.16亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 1,424,269,934.08 | 1,449,605,634.51 | 1,783,397,625.56 | 1,766,578,746.14 |
| 交易性金融资产 | 2,706,000,000 | 2,569,000,000 | 2,183,000,000 | 1,925,000,000 |
| 应收票据及应收账款 | 1,759,471,783.3 | 1,471,866,541.37 | 1,523,070,678.11 | 1,652,807,186.11 |
| 应收账款 | 1,759,471,783.3 | 1,471,866,541.37 | 1,523,070,678.11 | 1,652,807,186.11 |
| 应收款项融资 | 70,830,187.59 | 95,367,480.99 | 124,719,815.04 | 129,551,372.06 |
| 预付款项 | 116,131,433.4 | 49,408,564.16 | 64,498,282.66 | 49,000,271.93 |
| 其他应收款合计 | 76,319,179.84 | 21,987,590.49 | 76,676,360.78 | 69,061,417.74 |
| 存货 | 695,228,046.98 | 756,783,513.22 | 880,805,703.23 | 743,426,024.3 |
| 其他流动资产 | 26,367,124.6 | 48,933,107.86 | 13,012,277.11 | 33,751,107.89 |
| 流动资产合计 | 6,874,617,689.79 | 6,462,952,432.6 | 6,649,180,742.49 | 6,369,176,126.17 |
| 非流动资产: | | | | |
| 长期股权投资 | 146,322,299.11 | 143,911,402.44 | 102,294,193.23 | 100,538,765.58 |
| 其他权益工具投资 | 51,162,880.55 | 51,162,880.55 | 53,149,740.71 | 53,149,740.71 |
| 投资性房地产 | 49,246,225.35 | 49,804,107.48 | 50,361,989.61 | 50,919,871.74 |
| 固定资产 | 1,232,754,863.17 | 1,222,358,056.9 | 1,220,204,283.93 | 1,206,808,225.26 |
| 在建工程 | 321,073,178.77 | 365,937,574.8 | 298,236,727.84 | 316,710,873.33 |
| 使用权资产 | 40,494,075.26 | 45,920,686.5 | 52,068,770.66 | 48,727,154.05 |
| 无形资产 | 285,185,138.31 | 249,078,026.8 | 227,483,092.71 | 233,285,880.09 |
| 开发支出 | 291,298,502.01 | 308,766,710.25 | 257,060,672.38 | 212,932,644.4 |
| 长期待摊费用 | 205,828,376.86 | 220,263,027.14 | 57,692,367.98 | 74,850,584.42 |
| 递延所得税资产 | 75,776,840.3 | 73,903,677.15 | 43,033,724.7 | 67,389,153.79 |
| 其他非流动资产 | 68,878,318.34 | 29,173,337.55 | 68,923,730.47 | 54,035,900.01 |
| 非流动资产合计 | 2,768,020,698.03 | 2,760,279,487.56 | 2,430,509,294.22 | 2,419,348,793.38 |
| 资产总计 | 9,642,638,387.82 | 9,223,231,920.16 | 9,079,690,036.71 | 8,788,524,919.55 |
| 流动负债: | | | | |
| 短期借款 | 61,000,000 | 30,000,000 | - | 40,000,000 |
| 应付票据及应付账款 | 622,339,871.09 | 556,948,702.08 | 494,548,620.84 | 508,119,418.66 |
| 其中：应付票据 | 309,787,375.97 | 311,845,853.58 | 238,924,131.08 | 243,793,719.29 |
| 应付账款 | 312,552,495.12 | 245,102,848.5 | 255,624,489.76 | 264,325,699.37 |
| 合同负债 | 70,114,770.08 | 30,013,269.51 | 28,068,373.6 | 38,203,845.41 |
| 应付职工薪酬 | 172,000 | 4,979,542.8 | - | - |
| 应交税费 | 151,682,401.48 | 154,795,451.32 | 181,359,832.06 | 210,944,094.15 |
| 其他应付款合计 | 276,024,864.44 | 295,302,487.37 | 184,794,764.45 | 232,193,629.59 |
| 一年内到期的非流动负债 | 18,147,548.7 | 17,794,114.83 | 20,817,318.83 | 19,376,532.21 |
| 其他流动负债 | 7,854,030.83 | 2,405,967.28 | 2,596,190.8 | 3,897,595.15 |
| 流动负债合计 | 1,207,335,486.62 | 1,092,239,535.19 | 912,185,100.58 | 1,052,735,115.17 |
| 非流动负债: | | | | |
| 长期借款 | 230,000 | 230,000 | 230,000 | 230,000 |
| 租赁负债 | 15,573,434.63 | 19,694,594.05 | 25,675,927.04 | 24,496,108.59 |
| 预计负债 | 24,373,279.47 | 33,543,279.47 | 24,635,621.34 | 24,635,621.34 |
| 递延收益 | 49,628,478.66 | 49,628,478.66 | 41,406,697.8 | 41,406,697.8 |
| 非流动负债合计 | 89,805,192.76 | 103,096,352.18 | 91,948,246.18 | 90,768,427.73 |
| 负债合计 | 1,297,140,679.38 | 1,195,335,887.37 | 1,004,133,346.76 | 1,143,503,542.9 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 1,015,786,583 | 1,015,786,583 | 1,015,786,583 | 1,016,176,792 |
| 资本公积 | 281,302,264.12 | 281,302,264.12 | 277,352,051.09 | 281,453,147.68 |
| 减:库存股 | 68,300,800.4 | 68,300,800.4 | 68,300,800.4 | 98,855,937 |
| 其他综合收益 | -1,113,608.34 | -1,113,608.34 | 873,251.82 | 873,251.82 |
| 盈余公积 | 508,088,396 | 508,088,396 | 508,088,396 | 508,088,396 |
| 未分配利润 | 6,638,785,694.04 | 6,321,371,740.37 | 6,370,084,788.26 | 5,964,532,128.93 |
| 归属于母公司股东权益合计 | 8,374,548,528.42 | 8,057,134,574.75 | 8,103,884,269.77 | 7,672,267,779.43 |
| 少数股东权益 | -29,050,819.98 | -29,238,541.96 | -28,327,579.82 | -27,246,402.78 |
| 股东权益合计 | 8,345,497,708.44 | 8,027,896,032.79 | 8,075,556,689.95 | 7,645,021,376.65 |
| 负债和股东权益合计 | 9,642,638,387.82 | 9,223,231,920.16 | 9,079,690,036.71 | 8,788,524,919.55 |
| 公告日期 | 2026-04-18 | 2026-04-18 | 2025-10-25 | 2025-07-30 |
| 审计意见(境内) | | 标准无保留意见 | | |